CAS: 950769-58-1; 1-(5-(Tert-Butyl)Isoxazol-3-yl)-3-(4-(7-(2-Morpholinoethoxy)Benzo[d]Imidazo[2,1-B]Thiazol-2-yl)Phenyl)Urea

上下游产品

2-(4-aminophenyl)-7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazole 5-tert-butyl-3-isoxazolyl is°Cyanate 2-(morpholin-4-yl)ethanol N-(5-tert-butylisoxazol-3-yl)-N'-[4-(7-hydroxyimidazo[2,1-b][1,3]benzothiazol-2-yl)phenyl]urea

3-氨基-5-叔丁基异唑置于4-二甲氨基吡啶,Potassium Carbonate,三乙胺体系中,用 四氢呋喃 作为反应溶剂,化学反应 21.0H,反应生成 N-(5-叔丁基-异噁唑-3-基)-N-{4-[7-(2-吗啉-4-基乙氧基)咪唑并[2,1-B][1,3]苯并噻唑-2-基]苯基}脲
参考文献: Process For The Preparation Of Imidazo[2,1-B][1,3]Benzothiazole Derivatives[fr] Procédé De Préparation De Dérivés D'Imidazo[2,1-B][1,3]Benzothiazole
标题: Process For The Preparation Of Imidazo[2,1-B][1,3]Benzothiazole Derivatives[fr] Procédé De Préparation De Dérivés D'Imidazo[2,1-B][1,3]Benzothiazole
摘要:本文提供了一种制备n-(5-Tert-丁基异噁唑-3-基)-N'-{4-[7-(2-吗啉-4-基-乙氧基)咪唑[2,1-F][1,3]苯并噻唑-2-基]苯基}脲,或其药学上可接受的盐,溶剂化合物,水合物或多晶形式的方法.n-(5-Tert-丁基异噁唑-3-基)-N'-{4-[7-(2-吗啉-4-基-乙氧基)咪唑[2,1-F][1,3]苯并噻唑-2-基]苯基}脲可用于治疗,预防和/或管理疾病或症状,包括但不限于增殖性疾病,Flt-3介导的疾病和癌症.n-(5-Tert-丁基异噁唑-3-基)-N'-{4-[7-(2-吗啉-4-基-乙氧基)咪唑[2,1-F][1,3]苯并噻唑-2-基]苯基}脲的结构如下所示:

专利信息

专利号:US-2025206743-A1
优先权日:2022-03-25
标 题:Tyk2 inhibitor synthesis and intermediates thereof
发明人：MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
权利人:TAKEDA PHARMACEUTICALS CO
摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

专利号:WO-2025128098-A1
优先权日:2023-12-13
标 题 :Solid oral dosage forms, kits, and methods of using the same
发明人：LI YING; LANGER ROBERT; TRAVERSO CARLO
权利人:MASSACHUSETTS INST TECHNOLOGY; BRIGHAM & WOMENS HOSPITAL INC
摘要:Provided herein are solid oral dosage forms, methods, and kits useful, e.g, for the extension of the residence time of active pharmaceutical agents in vivo by the synthesis of a polymer in situ in a subject. In particular, the solid oral dosage forms, methods, and kits disclosed herein are particularly useful for drugs that require more than once daily administration (e.g, drugs that have short half-lives).

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-12390420-B1
优先权日:2024-10-22
标题 :Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof
发明人：EGUCHI MASAKATSU
权利人:BRYET US INC
摘要:The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.

专利号:US-12180228-B2
优先权日:2019-06-05
标题:Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
发明人：MOVASSAGHI MOHAMMAD; OLSSON CHASE ROBERT; SCOTT TONY Z; CHEAH JAIME; PAYETTE JOSHUA NATHANIEL
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:The present disclosure provides, e.g., compounds, compositions, kits, methods of synthesis, and methods of use, involving epipolythiodiketopiperazines and polythiodiketopiperazines.

专利号:WO-2024132278-A1
优先权日:2022-12-20
标题:Synthesis, pharmacology and use of new water-soluble and selective fms-like tyrosine kinase 3 (flt3) inhibitors
发明人：MAHBOOBI SAVOSH; WIRTH LUKAS; PONGARTZ HERWIG; SELLMER ANDREAS
权利人:UNIV REGENSBURG
摘要:The present application relates to compounds of formula (I) for inhibiting FLT3. The present application further relates to a composition, preferably pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt thereof and comprising a pharmaceutically acceptable excipient and/or carrier. The present application also relates to a compound or composition for use in medicine. The present application also relates to a compound or composition for use in a method of preventing or treating cancer, preferably blood cancer, more preferably leukemia, even more preferably acute myeloid leukemia (AML). Furthermore, the present application relates to a method of preparing a compound.